LauraQuan ManChowMDFRCPC

Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer

Professor and associate chair of education, department of oncology, dell medical school, university of Texas at Texas Associate director clinical research, director of head and neck and lung cancer and clinical immunotherapy, livestrong cancer institutes

Join to view full profile

Dr. Chow is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chow's full profile

Already have an account?

Office
825 Eastlake Ave E
Seattle, WA 98109
Phone+1 206-288-7222

Education & Training

University of British ColumbiaClass of 1999

Certifications & Licensure

WA State Medical License 2009 - 2026
TX State Medical License 2019 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck Start of enrollment: 2011 Jun 01
Completed
Phase 1
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery Start of enrollment: 2011 Dec 01
Completed
Phase 1
MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). Start of enrollment: 2014 Mar 24
Completed
Phase 1
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Start of enrollment: 2017 Feb 23
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

ACR Appropriateness Criteria® Staging and Post-Therapy Assessment of Head and Neck Cancer.
, Maria K Gule-Monroe, Susana Calle, Bruno Policeni, Amy F Juliano
Journal of the American College of Radiology. 2023-11-01
12 citations
Biomarkers predictive of response to pembrolizumab in head and neck cancer.
David G Pfister, Robert I Haddad, Francis P Worden, Jared Weiss, Ranee Mehra
Cancer Medicine. 2023-03-01
20 citations
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
Tae Won Kim, Howard A Burris, Maria J de Miguel Luken, Michael J Pishvaian, Yung-Jue Bang
Clinical Cancer Research. 2022-08-15

Lectures

A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Cancers Once Linked to Tobacco Use Now More Closely Connected to HPV, Texas Study SaysJanuary 19th, 2020
Fred Hutch Tip Sheet: Epstein-Barr Virus, CMV Breakthroughs, Immunotherapy Advances, Brain Cancer and Head and Neck TumorsMay 7th, 2018
Seven Doctors Leaving Centretown Medical Clinic en MasseOctober 5th, 2017
Join now to see all